July 11, 2007 (Geneva, Switzerland) - Low-molecular-weight-heparin (LMWH) prophylaxis in nonsurgical patients at increased risk for venous thromboembolism (VTE) should be extended for about a month ...

April 20, 2007 — Results of a randomized trial show a significant reduction in venous thromboembolism (VTE) events in stroke patients receiving the low-molecular-weight heparin enoxaparin ( Lovenox, ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Enoxaparin was superior to unfractionated heparin, with a 43% relative risk reduction of venous ...

Missed doses of prophylactic anticoagulation account for much of the deep vein thrombosis (DVT) that occurs in surgery and trauma patients, a study showed. Among 202 such patients admitted to a level ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Results of a multicenter, phase 3 study ...

Stakeholders concurred that the occurrence of VTE events is a significant public health concern. According to Ralph J. Riello III, PharmD, “It is a problem often that hospitals do not know that they ...

There is no gold standard for the prophylaxis of venous thromboembolism (VTE) for patients with acute ischemic stroke because of uncertainty regarding the efficacy of various anticoagulant agents.

In total hip or total knee arthroplasty, hypercoagulability typically begins on the operating table and a hypercoagulable state persists for up to 3 months after surgery. For that reason, it is ...

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long ...

The Appraisal Committee considered evidence submitted by the manufacturer of rivaroxaban and a review of this submission by the Evidence Review Group (ERG). The manufacturer's submission compared ...

Medical Compression Systems, Inc. (MCS), today announced new data further validating the use of the ActiveCare ® DVT prophylaxis compression system following total joint replacement procedures. The ...